Zenas BioPharma, Inc.
ZBIODrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ZBIO Earnings Report
EPS Est: $-0.89 | FQ end 2026-06
How ZBIO's past catalysts played out
Obexelimab
IgG4 Related Disease
Orelabrutinib
Multiple Sclerosis (MS) Primary Progressive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Obexelimab | Phase 3 | IgG4 Related Disease | - | - |
Orelabrutinib | Phase 3 | Multiple Sclerosis (MS) Primary Progressive | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Zenas BioPharma, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Zenas BioPharma, Inc.'s (ZBIO) pipeline across Phase 3. Its lead program is Obexelimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zenas BioPharma, Inc.'s next FDA catalyst?→
Zenas BioPharma, Inc.'s (ZBIO) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ZBIO biotech catalysts?→
Add ZBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zenas BioPharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.